Published on August 06, 2026
Donor Cell GATA3 Is Critical for Gut Pathogenic T Cell Effector Function and Intestinal Eosinophilia After Hematopoietic Cell Transplantation
by Alex Kadhim
A study in The Journal of Immunology from Purdue University, with collaborators at Cincinnati Children's, identifies donor-cell GATA3, a transcription factor which drives Th2 differentiation, as a central regulator of gut graft-versus-host disease (GVHD) after hematopoietic cell transplantation (HCT). GATA3 supported pathogenic CD4-positive T-cell accumulation in the intestine, early production of tissue-damaging granzyme A, and sustained GM-CSF-driven eosinophilic inflammation. Its broader role in blood-cell development constrains how it could be targeted therapeutically.
Intestinal GVHD is a major cause of illness and death after HCT, but the T-helper-cell programs responsible for sustained gut damage remain incompletely characterized. While GATA3 regulates Th2 and allergic responses and is expressed in gut-resident regulatory T cells, the authors hypothesized an additional role in pathogenic intestinal T cells with mixed Th1/2 characteristics. RNA-sequencing data from 33 human gastrointestinal biopsies (18 GVHD, 15 control) were reanalyzed, followed by mechanistic experiments in allogeneic mouse transplantation models. Wild-type and STAT6-deficient donor T cells were compared to determine how GATA3 expression is induced.
Human GVHD biopsies were enriched for Th1 (NES 1.45; FDR=0.03), Th17 (NES 1.66; FDR=0.004), and GATA3-regulated gene signatures (NES 1.75; FDR=0.0007). In mice, more than 90% of GATA3-positive intestinal donor CD4 T cells co-expressed T-bet. GATA3 deletion significantly reduced early colon shortening (p=0.0086), total intestinal donor cells (p=0.012), and donor CD4 T cells (p=0.002), while donor CD8 T-cell numbers were not significantly affected. Loss of GATA3 also reduced granzyme A and Csf2 expression, prevented chronic colitis-like changes at days 28–35, and decreased intestinal eosinophil accumulation and activation. Systemic deletion, however, impaired competitive reconstitution of T cells, B cells, granulocytes, and monocytes. Selective disruption of GATA3 in donor T cells or the intestine, or of the downstream GM-CSF–eosinophil pathway, may therefore reduce intestinal GVHD while avoiding broad suppression of hematopoietic recovery.
Reference:
Yeo FJ, Wang M, Park S, et al. Donor cell GATA3 is critical for gut pathogenic T cell effector function and intestinal eosinophilia after hematopoietic cell transplantation. J Immunol. 2026;215(7):vkag190. https://doi.org/10.1093/jimmun/vkag190
![]()